RxDoctor Payments Data

Kyle Speakman, MD

Family Medicine · Marion, INNPI 1104269240

Payments from drug & device makers

$2,653in general payments, 2019–2025

Across 154 payments — averaging $17.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$701
  • Novo Nordisk$538
  • Bayer$339
  • AstraZeneca$293
  • Axsome Therapeutics, Inc.$149
  • Pfizer$142
  • plus $491 from 12 others

What the payments were for

  • Food & beverage$2,640100%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,653 in reported general payments places this provider in the 75th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$96,511
Medicare patients
324
Services billed
2,999

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban124$175,516
JardianceEmpagliflozin105$145,295
JanuviaSitagliptin Phosphate101$131,609
OzempicSemaglutide73$91,940
Trelegy ElliptaFluticasone/Umeclidin/Vilanter68$88,362
XareltoRivaroxaban34$35,316
Tresiba Flextouch U-200Insulin Degludec17$34,127
MounjaroTirzepatide19$31,920
Breo ElliptaFluticasone/Vilanterol19$18,436
MyrbetriqMirabegron16$18,393
Combivent RespimatIpratropium/Albuterol Sulfate19$14,997
FarxigaDapagliflozin Propanediol15$12,838
Lantus SolostarInsulin Glargine,hum.Rec.Anlog38$7,360
Atorvastatin Calcium872$6,917
Albuterol Sulfate HfaAlbuterol Sulfate218$6,840

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$142$175,516124 claims
GSKTrelegy Ellipta, Breo Ellipta$58$106,79887 claims
Novo NordiskOzempic$538$91,94073 claims
Lilly USA, LLCMounjaro$19$31,92019 claims
Astellas Pharma US IncMyrbetriq$13$18,39316 claims
AstraZenecaFarxiga, Symbicort$293$17,43932 claims
AbbVieSynthroid$701$2,64334 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Marion

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →